Theranos whistleblower warns AI boom risks repeat of fraud like Theranos
Tyler Shultz, a former Theranos employee and whistleblower, compared today’s AI funding frenzy to the company’s $10 billion peak valuation despite its fraudulent blood-testing technology. Shultz told The San Francisco Standard that investors now hand out hundreds of millions in early-stage funding with little due diligence, a pattern he fears could enable deception at scale in AI startups. He…
Key points
- Theranos whistleblower Tyler Shultz compares AI funding to Theranos’ $10B valuation despite fraudulent tech
- Shultz warns investors lack due diligence, enabling deception in AI startups with vague claims or proprietary barriers
- Haemanthus, Holmes’ new diagnostics venture, reportedly raised $20M, raising concerns about repeat schemes
Theranos whistleblower Tyler Shultz warns that the AI boom is ‘a great opportunity to go deceive people’
TechCrunch AI · 30 October 2026
Loading the full article…
This text was published by TechCrunch AI and written by Amanda Silberling. It is reproduced here with attribution so you can read it in full; the rights remain with the publisher. Read it at the source ↗
The headline, key points and digest above were generated by Digest AI's editorial model from the linked sources. Automated summaries can contain errors: the sources are the record. Spotted a mistake? Tell us. Published by Martin K., who runs Digest AI and handles corrections.
More in Society & Work
All →- Musk and Zuckerberg adopt Trump’s ‘superintelligence’ term on earnings calls · 1 src
- OpenAI outlines four-layer system to detect AI misalignment in advanced models · 4 src
- CrowdStrike says China-linked hackers used DeepSeek to target 200+ groups · 2 src
- Researcher wins first Title VII AI exemption for humanist beliefs · 2 src
- MIT professor Eric So warns AI reliance erodes human cognitive skills · 1 src
Comments
via GitHub Discussions